title: The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy.
authors.forename: M
authors.initials: M
authors.lastname: D'Andrea
authors.forename: L
authors.initials: L
authors.lastname: Nosotti
authors.forename: F
authors.initials: F
authors.lastname: Pimpinelli
authors.forename: M L
authors.initials: ML
authors.lastname: Dessanti
authors.forename: A
authors.initials: A
authors.lastname: Paviglianiti
authors.forename: L
authors.initials: L
authors.lastname: Miglioresi
authors.forename: A
authors.initials: A
authors.lastname: Morrone
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D018890:Chemoprevention; D064420:Drug-Related Side Effects and Adverse Reactions; D006509:Hepatitis B / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D019259:Lamivudine